Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

305

Full text

258

Free full text

107

Publication Types

Journal Article

311

Research Support, Non-U.S. Gov't

154

Review

114

Randomized Controlled Trial

Clinical Trial

Research Support, N.I.H., Extramural

Comparative Study

Multicenter Study

Observational Study

Systematic Review

Clinical Trial, Phase II

Research Support, U.S. Gov't, Non-P.H.S.

Clinical Trial, Phase I

Meta-Analysis

Research Support, U.S. Gov't, P.H.S.

Editorial

Clinical Trial, Phase III

Comment

Controlled Clinical Trial

Validation Study

Research Support, N.I.H., Intramural

Letter

Case Reports

Historical Article

Clinical Trial, Phase IV

Pragmatic Clinical Trial

Publication Year

From

Quick links

Individual year

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

2000

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Potassium Channel Blockers""[mesh_terms]

320 Results

Searching titles within these results

Drug-Induced QT/QTc Interval Shortening: Lessons from Drug-Induced QT/QTc Prolongation.

Marek Malik

Drug safety 2017;39(7):647-59

Full Text

Abstract

Pharmacological treatment of atrial fibrillation: mechanisms of action and efficacy of class III drugs.

Federico Lombardi, Paolo Terranova

Current medicinal chemistry 2006;13(14):1635-53

Full Text

Abstract

Guidelines for Potassium Channel Blocker Use.

Anne M Gillis

Cardiac electrophysiology clinics 2017;8(2):495-501

Full Text

Abstract

Dalfampridine improves slowed processing speed in MS: Picking up the pace.

James F Sumowski, Nils Muhlert

Neurology 2020;93(8):325-326

Full Text

Dofetilide: a new class III antiarrhythmic agent.

R Al-Dashti, M Sami

The Canadian journal of cardiology 2001;17(1):63-7

Full Text

Abstract

Non-cancer to anti-cancer: investigation of human ether-a-go-go-related gene potassium channel inhibitors as potential therapeutics.

Vaishali M Patil, Anand Gaurav, Priyanka Garg, Neeraj Masand

Journal of the Egyptian National Cancer Institute 2021;33(1):33

Full Text

Abstract

Molecular Basis of Cardiac Delayed Rectifier Potassium Channel Function and Pharmacology.

Wei Wu, Michael C Sanguinetti

Cardiac electrophysiology clinics 2017;8(2):275-84

Free Full Text

Abstract

Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis.

Scott Weir, Risa Torkin, Herbert R Henney

Current medical research and opinion 2014;29(12):1627-36

Full Text

Abstract

Current strategies for the discovery of K+ channel modulators.

Deju Ye, Jiang Wang, Kunqian Yu, Yu Zhou, Hualiang Jiang, Kaixian Chen, Hong Liu

Current topics in medicinal chemistry 2009;9(4):348-61

Full Text

Abstract

K+ channel structure-activity relationships and mechanisms of drug-induced QT prolongation.

Colleen E Clancy, Junko Kurokawa, Michihiro Tateyama, Xander H T Wehrens, Robert S Kass

Annual review of pharmacology and toxicology 2003;43():441-61

Full Text

Abstract

Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis.

D Weller, L Lörincz, T Sutter, K Reuter, M Linnebank, M Weller, B Zörner, L Filli

Journal of the neurological sciences 2021;416():116978

Free Full Text

Abstract

5-(Indol-2-yl)pyrazolo[3,4-]pyridines as a New Family of TASK-3 Channel Blockers: A Pharmacophore-Based Regioselective Synthesis.

Magdalena Platzk, David Ramírez, Melissa Mejia-Gutierrez, Braulio Insuasty, Susanne Rinné, Aytug K Kiper, Thomas Müller, Niels Decher, Jairo Quiroga, Pedro De-la-Torre, Wendy González

Molecules (Basel, Switzerland) 2021;26(13):3897

Free Full Text

Abstract

Medical treatment of acquired nystagmus.

Eric Eggenberger, David Ehrhardt

Current opinion in ophthalmology 2013;23(6):510-6

Full Text

Abstract

Natural modulators of large-conductance calcium-activated potassium channels.

Antonio Nardi, Vincenzo Calderone, Silvio Chericoni, Ivano Morelli

Planta medica 2004;69(10):885-92

Full Text

Abstract

Potassium Channel Remodeling in Heart Disease.

Vincent Algalarrondo, Stanley Nattel

Cardiac electrophysiology clinics 2017;8(2):337-47

Full Text

Abstract

Results: 1 – 15 / 320

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Potassium Channel Blockers""[mesh_terms]

Drug-Induced QT/QTc Interval Shortening: Lessons from Drug-Induced QT/QTc Prolongation.

Pharmacological treatment of atrial fibrillation: mechanisms of action and efficacy of class III drugs.

Guidelines for Potassium Channel Blocker Use.

Dalfampridine improves slowed processing speed in MS: Picking up the pace.

Dofetilide: a new class III antiarrhythmic agent.

Non-cancer to anti-cancer: investigation of human ether-a-go-go-related gene potassium channel inhibitors as potential therapeutics.

Molecular Basis of Cardiac Delayed Rectifier Potassium Channel Function and Pharmacology.

Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis.

Current strategies for the discovery of K+ channel modulators.

K+ channel structure-activity relationships and mechanisms of drug-induced QT prolongation.

Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis.

5-(Indol-2-yl)pyrazolo[3,4-]pyridines as a New Family of TASK-3 Channel Blockers: A Pharmacophore-Based Regioselective Synthesis.

Medical treatment of acquired nystagmus.

Natural modulators of large-conductance calcium-activated potassium channels.

Potassium Channel Remodeling in Heart Disease.

Results for
""Potassium Channel Blockers""[mesh_terms]